Business » Industry

Updated: September 2, 2013 22:09 IST

Novo Nordisk to launch Tresiba insulin injection

Special Correspondent
Comment (6)   ·   print   ·   T  T  
Melivan D'souza, Managing Director, Nova Nordisk India at a press conference in Mumbai on Monday. Photo: Paul Noronha
Melivan D'souza, Managing Director, Nova Nordisk India at a press conference in Mumbai on Monday. Photo: Paul Noronha

Will be made available in FlexTouch, a pre-filled pen

Danish pharmaceutical major Novo Nordisk, on Monday, said it would soon launch its insulin injection Tresiba (insulin degludec) in India.

Novo Nordisk is the leading manufacturer of insulin in the world, and Tresiba, the new basal insulin, is used for the treatment of Type 1 and Type 2 diabetes.

The once-daily use medicine has a duration of action beyond 42 hours, and allows flexibility in daily dosing time without reducing efficacy , Melvin D’Souza, Managing Director, Novo Nordisk India, said, while addressing a media conference here. “Tresiba will be launched towards the end of the year, and the price of the product will be announced closer to the launch date,” he said.

Novo Nordisk India has 15 per cent share in the diabetes care market with a significant share in insulin, and is hopeful of growing at 15 per cent per annum, Mr. D’Souza added. Tresiba will be made available in FlexTouch, a pre-filled pen with an easy touch button, enabling doses of up to 80 units in a single injection.

Novo Nordisk ties up with IAD

In a bid to provide doctors access to updated and scientific information on insulin therapy, Novo Nordisk has tied up with Indian Academy of Diabetes (IAD) to launch a massive doctor education programme – Master Class in Insulin.

India has 65 million diabetes patients and 130 million pre-diabetes patients, said Dr. Shashank Joshi, President, IAD. “Yet, only 6 million receive appropriate treatment.

The programme will use the peer-to-peer model where the focus will be on engaging national leaders who are pioneers in ‘insulinology’ and ‘diabetology’, and these doctors will further train 1,000 primary care physicians across the country.”

More In: Industry | Business

Novonordisk sponsoring CME violating the norms led by medical council of India (MCI). Knowledge driven by marketing strategy only confused physician lead to prescription of costly medicine. Such type of bias knowledge sharing platform need to be bann immediately .The society form under these pharmaceutical banner need to shut down . Health Ministry should striclty control such bias CME where speakers donot have any independent views. They only show the positive results of drug sold by the pharmaceutical which is sponsoring .I worked as medical advisor in a pharma company for 1 year and know what ethics they follow in India .They just fool doctors by so called specialist doctors as a speaker and make strategy to rip own benefit rather than paitent benefit. Pharmaceutical code of ethics still not becoming mandatory in India .

from:  Dr Ajay Mittal
Posted on: Sep 4, 2013 at 16:28 IST

I agree with Rajeev. If the medical corresponds of reputed papers instead of just reporting the media feed by pharma companies give a comparative cost the efficacy and affordability will help huge affected population affected by diabetes in taking a informed decision

from:  K.Sivakameswar
Posted on: Sep 4, 2013 at 08:31 IST

I agree with you Deepak. IT authority should exempt such expenses & government should also subsidized such medicine which is expensive & people can not afford this.

A lot needs to be done for millions of people suffering from Diabetes in India. MNC should not have sole motto of market share & mint money. They should work for social cause too at the same time.

from:  prakash prohit
Posted on: Sep 3, 2013 at 12:19 IST

NOVO NORDISK only making money on diabetics by promoting different version of insulin without any clear benefit .All these hip hops are marketing gimmick.These insulin may lead to gastric cancer and some unwanted side effects .Tweaking drugs for commercial gain should be discouraged by our Physician. Recently USFDA also put lot of questions on me too drug ,as they are commercial purpose only not benefiting mankind.
Pharmaceutical Company now a days launch new molecule without significant benefit to increase its revenue ,they are becoming like automobile company which launches new model to attarct customer .I highly recommend not to prescribe this to poor and middle class people of India . Use Generic affordable insulin (of course in those you have confiendence )

from:  Dr MP Das
Posted on: Sep 3, 2013 at 12:13 IST

Will the Tresiba Insulin be within the reach of common man. As rightly said 65 million patients and <10% can afford treatment. Dr. do prescribe insulin to all, but then Dr. do not care whether the patient can afford the medicines prescribed in India. Income Tax Dept should be the First Govt Dept to recognizes Diabetics and offer tax exemptions for medication and Insurance cover, which is ridiculously high and beyond reach. This will help the 65 million patients. Novo Nordisk will encash on the situation, making millions for its promoter and politicians who have helped approve this expensive drug.

from:  Deepak Menon
Posted on: Sep 3, 2013 at 11:25 IST

There is no evidence that this form of Insulin is superior to Cheaper Insulatard (Isophane Insulin) (another long acting Insulin)-Your medical correspondent should research this and present a balanced view about these newer Insulins. I would like to see reports publishing the comparison between the different kinds of Insulin and the costs!!In Diabetes it is professional education covering diet, exercise, Blood Pressure, Cholesterol, Eye evaluation and use of Statins with overall blood sugar control without developping hypoglycemia (low Blood sugars)--all these parameters should be evaluated.Please look at the recent article in the lancet covering these newer insulins-there is no difference and the costs are substantially higher.

from:  Rajiv
Posted on: Sep 3, 2013 at 11:00 IST
Show all comments
This article is closed for comments.
Please Email the Editor

Commodity prices

Take a look at the prices of various commodities in Chennai here»





Recent Article in Industry

IFCI Q4 profit down by 30%

State-owned IFCI on Tuesday reported a 30 per cent decline in its net profit at Rs 120 crore for the quarter ended March 2015 on the bac... »